Many of oncogenes and tumor suppressor genes have been found to exert variable and even opposing roles in different kinds of tumors or at different stages of cancer development. Here we showed that tumorigenic potential of mouse embryonic carcinoma P19 cells cultured in adherent plates (attached-P19-cells) was suppressed by a chemotherapeutic agent, 5-aza-2 ′ -deoxycytidine (ZdCyd), whereas the higher pro-tumorigenicity of P19 cells growing in suspension (detached-P19-cells) was generated by the ZdCyd treatment. Surprisingly, p53 activity was highly up-regulated by ZdCyd in both growing conditions. By our developed computational approaches, we revealed that there was a significant enrichment of apoptotic pathways in the ZdCyd-induced p53-dominant gene-regulatory network in attached P19 cells, whereas the pro-survival genes were significantly enriched in the ZdCyd-induced p53 network in detached P19 cells. The protein-protein interaction network of the ZdCyd-treated detached P19 cells was significantly different from that of ZdCyd-treated attached P19 cells. On the other hand, inhibition of p53 expression by siRNA suppressed the ZdCyd-induced tumorigenesis of detached P19 cells, suggesting that the ZdCyd-activated p53 plays oncogenic function in detached P19 cells. Taken together, these results indicate a context-dependent role for the ZdCyd-activated p53-dominant network in tumorigenesis.
Introduction
It is a conventional way to apply terms 'oncogene' or 'tumor suppressor gene' to particular genes for their tumorigenic potential. However, a number of these genes have showed variable roles in different kinds of tumors or during different stages of cancer development (Quigley and Balmain, 2009; Lorente-Trigos et al., 2010) . Trp53 is a well-known tumor suppressor gene, of which mutations occur in approximately half of all human cancers (Levine and Oren, 2009) . However, Trp53 mutations were encountered in neuroblastoma tumors as low frequencies (,2%) and even failed to be detected in embryonic carcinoma (EC) cells (Peng et al., 1993; Tweddle et al., 2003) . In addition, recent evidences have revealed that the p53 reactivation could suppress high-grade tumors but not the tumors at early stages (Feldser et al., 2010; Junttila et al., 2010) .
The complexity of p53 functions results from p53, as a 'master regulator', controlling expression of multiple gene targets (McMurray et al., 2008; Menendez et al., 2009) . More than 100 p53 target response elements (REs) have been functionally validated in human and mouse samples (Menendez et al., 2009) , and a genome-wide analysis suggests that p53 could bind thousands of sites in the genome (Kaneshiro et al., 2007) . In addition, Menendez et al. (2006) showed that the sequence as short as 10 bases could function as p53 target RE, which implies that there are more extensive p53-targeted genes in the genome than we previously expected. On the other hand, p53 itself is regulated by multiple factors (Kruse and Gu, 2009) . It is known that p53 can be phosphorylated by a number of DNA-damage-related kinases such as ATM, ATR, DNA-PK, Chk1, and Chk2, and can be modified by acetylation, methylation, sumoylation, and neddylation (Kruse and Gu, 2009) . The more complicated situation is that p53 can be regulated by its targets. Typically, oncogene Mdm2 is transcriptionally up-regulated by p53, whereas p53 stability is suppressed by MDM2 protein (Kubbutat et al., 1997; Shieh et al., 1997) . This negative feedback loop generates the p53-Mdm2 oscillator that can determine cell fate after DNA damage with the help of other regulating factors (Zhang et al., 2009 (Zhang et al., , 2011 . Taken together, the functions of p53 rely on its network, in which p53 is a main 'hub' controlling multiple gene nodes as well being regulated by multiple factors (Vogelstein et al., 2000; Harris and Levine, 2005) .
Murine EC cells retain pluripotent potential that is similar to embryonic stem (ES) cells (Knoepfler, 2009) . In addition, a previous report showed that human EC cells had a transcription profile similar to human ES cells, and was used as a model of early human development (Sperger et al., 2003) . Recently, we have developed a feasible induction system that allows direct and efficient differentiation of neural stem cells from mouse P19 EC cells, in which P19 cells are aggregated as embryonic bodies in bacterial petri dishes in N2B27 serum-free medium for 4 days (Xia et al., 2007) .
In addition, to be a developmental model, EC cells are also widely used as a model for analyzing the relationship between tumorigenicity and cell differentiation (Martin, 1975; Lutzker and Levine, 1996) . Numerous reports have showed that these EC cells could convert the phenotype from malignant into non-malignant during the process of cellular differentiation (Lutzker and Levine, 1996; Blelloch et al., 2004; Lagger et al., 2010) . Furthermore, since several reports showed that wild-type p53 proteins expressed in EC cells could be activated either by cancer-therapeutic agents such as 5-aza-deoxycytidine and cisplatin (Zamble et al., 1998; Beyrouthy et al., 2009) or by induced differentiation (Lutzker and Levine, 1996) , activation of p53 should play important roles in suppression of tumorigenicity in EC cells.
Based on our induction system, we analyzed tumorigenic potential of undifferentiated P19 cells cultured in adherent plates and differentiated P19 cells growing in suspension condition, respectively. In addition, tumorigenesis of these two different growing P19 cells was analyzed under the treatment of a chemotherapeutic agent, 5-aza-2 ′ -deoxycytidine (ZdCyd). These studies reveal an unexpected context-dependent role for the p53-dominant gene-regulatory network in tumorigenesis.
Results

Analysis of tumorigenic potential of P19 cells cultured in various conditions
After differential induction of P19 cells growing in suspension condition according to our previous protocol (Xia et al., 2007) , these detached P19 cells (Detached-P19, D-P19) had a significant reduction in their tumorigenic potential (Figure 1) , whereas P19 cells cultured on adherent plates (Attached-P19, A-P19) maintained their tumorigenic potential, including high efficiency of colony formation ( Figure 1A ) and tumorigenicity in nude mice ( Figure 1B and C) .
Since previous reports showed that DNA methylation inhibitors 5-azacytidine or ZdCyd induced EC-cell differentiation and restored cisplatin cytotoxic response to cisplatin-resistant EC cells (Choi et al., 2004; Beyrouthy et al., 2009; Banerjee and Bacanamwo, 2010) , we asked whether tumorigenic potential is reduced by treating P19 cells under the drug treatment. We found that treating A-P19 cells with ZdCyd (IA-P19) greatly reduced their tumorigenic potential, including low efficiency of colony formation ( Figure 1A) and tumorigenicity in nude mice ( Figure 1B and C). To our surprise, treating D-P19 cells with ZdCyd (ID-P19) resulted in even higher tumorigenicity in nude mice than that of A-P19 ( Figure 1B and C, compare A-P19 with ID-P19).
Since the ZdCyd treatment resulted in the similar inhibitory effect of 5-methylcytosine in both the attached and detached cells (Supplementary Figure S1) , we argue that DNA-methylation activity alone is not the determinant factor on tumorigenic potential of P19 cells. Histological analysis of resulting tumors of nude mice showed that tumors derived from A-P19 cells had a broad range of cell types like tumors derived from an ES cell line E14, whereas tumors derived from ID-P19 cells were similar to tumors generated from a cancer cell line A549 (Supplementary Figure S2) . Up-regulation of p53 activity by ZdCyd in both attached and detached growth conditions
To detect whether pro-tumorgenic genes are specifically up-regulated by ZdCyd in detached P19 cells, we measured mRNA expression profiles of P19 cells under these four growing conditions with Affymetrix microarrays. A total of 5931 differentially expressed genes were identified by two-way analysis of variance (ANOVA; Supplementary Table S1), and then these samples were hierarchically clustered (Materials and methods). We found that the gene-expression patterns of IA-P19 and ID-P19 were quite similar and clustered together ( Figure 2A ). This result suggests that the ZdCyd treatment generates the similar gene-expression patterns of P19 cells growing in both adherent and suspension conditions, although the ZdCyd treatment results in opposite tumorigenic potential of attached P19 cells and detached P19 cells (Figure 1) .
Activities of transcription factor (TF) are usually measured based on expression changes of their target genes. However, since transcription cofactors such as co-activators and co-repressors also involve in the regulation of TF activities (Perissi and Rosenfeld, 2005; Tan et al., 2008) , we defined TF activities with a novel hybrid graphical approach that integrates information of all mRNA expression changes of TFs, transcription cofactors and targets ( Figure 2B ). Note that we used the mRNA levels for cofactors and the TFs to approximate their protein levels in the present work. Then, we selected 53 TF candidates that should be presented in both KEGG and TRED databases, and then calculated TF activity score (TFAS) for each TF with a Boolean formula derived from the graphical sketch in Figure 2B based on the microarray data (Supplementary Table S2 ; see Materials and methods). Linear regression showed that the correlation between TFAS and TF's mRNA change is much stronger when TF's mRNA is down-regulated than up-regulated (Supplementary Figure S3) , which suggests that reducing the mRNA expression level is much more efficient than increasing that in affecting TF activity.
By further statistical calculations, 21 TFs with significant TFAS values were identified from these 53 selected TFs (Supplementary Table S2 and Figure 2C) . Surprisingly, the tumor suppressor gene p53 under the ZdCyd treatment presented the most significant TFAS values in both growing conditions ( Figure 2C ). To confirm this observation, we measured the protein levels of p53, phosphorylated p53, and the p53-target p21 with western blotting approach. The results showed that the ZdCyd treatment activated p53 proteins of P19 cells in both attached and detached growth conditions ( Figure 2D ), which is in agreement with our calculations of high TFAS values of p53 in both growth conditions ( Figure 2C ). In addition, the mRNA level of p53 was highly up-regulated in ZdCyd-treated detached P19 cells ( Figure 3A , right panel). Taken together, these results suggest that the ZdCyd-induced p53 activation inhibits the tumorigenic potential of attached P19 cells, whereas the the ZdCyd-induced p53 activation promotes the tumorigenic potential of detached P19 cells. ZdCyd-induced oncogenic function of p53 in detached P19 cells relies on a special p53-regulatory network, which should be different from that in ZdCyd-treated attached P19 cells. Based on our gene expression data and public database, we developed a new hybrid graphical approach (Supplementary Figure S4 ; see Materials and methods) to construct the ZdCyd-induced active gene-regulatory networks of P19 cells ( Figure 3A) . Figure 3A showed two important topological properties of the ZdCyd-induced active gene-regulatory networks. First, p53 was the most dominant 'hub' of the ZdCyd-induced gene-regulatory network in both attached P19 cells (with total 16 solid-line edges representing transcriptional regulatory relationships; Figure 3A , left panel) and detached P19 cells (with total 14 solidline edges; Figure 3A , right panel). Secondly, if we define that a TF-hub must have five or more solid-line edges that represent transcriptional regulatory relationships, there were more TF-hubs in the ZdCyd-induced gene-regulatory network in detached P19 cells (Stat3: 7, Rara: 7, Pou5f1: 6, Usf1: 5, Cebpb: 5; Figure 3A , right panel) than that in attached P19 cells (Jun: 7, Myc: 4; Figure 3A , left panel). These results indicate that the ZdCyd-induced gene-regulatory network is p53-dominant in both attached and detached P19 cells, but the topological structure of the network in attached P19 cells is quite different from that in detached P19 cells. (Usf1i) and negative control (nc) were shown in mean + SEM; *P ¼ 0.00208 for Dffb; *P ¼ 0.00241 for Cited1. (C) qPCR-measured expression levels of Pou5f1-targets under the treatment of shRNA (Pou5f1i) and negative control (nc) were shown in mean + SEM; *P ¼ 0.02; **P ¼ 0.008.
To confirm these predicted networks, we analyzed the regulation activity of TF Usf1, of which TFAS was significant in both growing-conditions ( Figure 2C) , with siRNA approach. The result of Usf1-knockdown showed that the expression of Dffb, which was predicted as a Usf1-target in adherent condition ( Figure 3A , left panel), was only significantly down-regulated in IA-P19 ( Figure 3B) , whereas the expression of Cited1, which was predicted as a Usf1-target in non-adherent condition ( Figure 3A, right panel) , was only significantly down-regulated in ID-P19 ( Figure 3B) . In contrast, an off-Usf1-target Ucp2, as a negative control, did not show significant gene-expression changes by Usf1 knockdown ( Figure 3B ). In addition, the relationship between TF Pou5f1, of which TFAS was significant only in suspension condition ( Figure 2C) , and its target Utf1 ( Figure 3A , right panel) was also confirmed with the same approach ( Figure 3C) .
Our results showed that gene components and their interactions within the ZdCyd-induced gene-regulatory networks of attached P19 cells were different from those of detached P19 cells ( Figure 3A) . To show the functional changes in the network level, we applied our newly developed network ontology analysis (NOA) to annotate these two networks . Traditional ontology methods such as DAVID regard a network as a list of gene, and annotate networks with gene set enrichment methods (Huang et al., 2009) . However, recent molecular network analysis reveals that the same list of genes with different interactions may perform different functions (Kitano, 2002) . Instead of focusing on gene list, NOA defining the function of edges can reveal the function change by network rewiring. We chose the union of these two networks as background, and tested the networks, respectively, with NOA. The NOA approach revealed that the significant enrichment of positive regulation of cell death and apoptotic pathways (P , 0.01) was only in the ZdCyd-induced gene-regulatory network of attached P19 cells, in which pro-apoptotic genes such as Nr3c1/GR, Perp, Trp53inp1, Ei24/PIG8, and Dffb were enriched (Supplementary Table S3 ). In contrast, the pathways of negative regulation of developmental process and cell differentiation were significantly enriched only in the ZdCyd-induced gene-regulatory network of detached P19 cells, in which prosurvival genes such as Rara, Pou5f1/Oct4, Cited1, Ghf4, and Ccnd1/Cyclin D1 were enriched (Supplementary Table S3 ). Taken together, these pro-apoptotic and pro-survival properties of the ZdCyd-induced gene-regulatory networks must be in response to anti-tumorigenesis of attached P19 cells and pro-tumorigenesis of detached P19 cells, respectively. Properties of the protein -protein interaction network in attached P19 cells are different from that in detached P19 cells
To extend our observation on the topological difference of gene-regulatory networks between attached P19 cells and detached P19 cells, we constructed a whole protein -protein interaction (PPI) network of P19 cells based on our gene-expression data and public databases (Supplementary Figure S5) . We first constructed a mouse referencing PPI network by integrating different databases including DIP36, MINT37, Biogrid38, and NIA. Secondly, based on this mouse referencing PPI network and the gene expression data of P19 cells (Supplementary Table S1 ), we predicted attached P19 cell PPI and detached P19 cell PPI networks, respectively (Supplementary Figure S5) . Then we calculated topological properties of these two networks in terms of degree distribution, path-length distribution, and clustering coefficient distribution ( Figure 4A and B) . Detailed topological properties of these two PPI networks were shown in Figure 4C . The results showed that the PPI network of detached P19 cells had higher density, degree, centralization, and clustering coefficient than that of attached P19 cells, suggesting that the topological structures of these two PPI networks are quite different.
Since the bio-molecular networks have been generally recognized to be composed of 'modules' (Hartwell et al., 1999; Barabási and Oltvai, 2004) , we developed a new bioinformatics approach to identify 13 'core protein-modules' that conserved in the PPI networks of both growing statuses (Supplementary Figure S5 and Table S4 ; see Materials and methods). The results showed that the inter-linkages between these 13 core protein modules in the network of attached status were quite different from that of detached status ( Figure 4D and Supplementary Figure S6 ). Importantly, module 5 containing p53 had strong connection with module 1 under attached growing condition, whereas module 5 completely lost the connection with module 1 and had newly strong connection with modules 3 and 12 under detached growing condition ( Figure 4D ). These results indicate that the relationships between building blocks of the PPI networks under attached status could be extensively re-wired in the detached status. Cisplatin-activated p53 could not promote tumorigenic potential of detached P19 cells
Since previous reports showed that cisplatin stimulated p53 activation of mouse EC cells (Zamble et al., 1998; Curtin et al., 2001; Kerley-Hamilton et al., 2005) , we wondered whether cisplatin could generate similar effects as the ZdCyd treatment did. The western blotting results showed that cisplatin activated p53 in P19 cells in adherent and suspension conditions, respectively ( Figure 5A) . Furthermore, the cisplatin treatment suppressed the tumorigenic potential of detached P19 cells, which showed the lowest efficiency either on colony formation ( Figure 5B ) or on tumorigenicity in nude mice ( Figure 5C and D) . These results indicate that the cisplatin-induced p53 in detached P19 cells retains its tumor-suppressing function, suggesting that the p53-promoted tumorigenesis of P19 cells is specifically generated based on the synergistic effect of both the ZdCyd-treatment and non-adherent growing condition. p53 knockdown erases ZdCyd-induced tumorigenic potential of detached P19 cells
The above observation that the ZdCyd-induced p53 activation promotes tumorigenesis of detached P19 cells implies that suppression of p53 activity will erase the ZdCyd-induced tumorigenic potential of detached P19 cells. To test this hypothesis, we knocked down endogenous Trp53 expression in P19 cells via the siRNA approach. Figure 6A and B showed that the downregulation of p53-mRNA and p53-protein levels in both growing conditions, respectively. As we expected, Trp53 knockdown resulted in the significant inhibition on ZdCyd-induced tumorigenicity of detached P19 cells ( Figure 6C and D) . On the other hand, Trp53 knockdown relieved the ZdCyd-generated tumor-suppression of attached P19 cells (Supplementary Figure  S7A and B). Taken together, these results further support the observation from the p53-gain function experiment that the ZdCyd-induced p53 activation as an oncogene behavior actually promotes tumorigenesis of detached P19 cells, while the ZdCyd-induced p53 activation retains its tumor-suppressing function in attached P19 cells.
We further analyzed the mRNA-expression profiles of these Trp53-knockdown cells by the microarray approach. The computational analysis showed that all 21 TFs lost their significances of TFAS values in both adherent and suspension growth conditions (compare Figure 6E with Figure 2C ), indicating that the p53 perturbation could spread out its regulatory effects at the global transcriptional level. In contrast to that the ZdCyd-induced mRNA expression patterns of both adherent and suspension-growing P19 cells were quite similar and clustered together (Figure 2A) , we found that the mRNA expression patterns of the p53-down-regulated samples were grouped based on the growing conditions ( Figure 6F ). These results suggest that the ZdCyd-induced p53 activation plays a dominant role to regulate the gene expressions at the global level in both growing conditions, whereas the particular growing condition of either adherent or suspension determines the gene expression patterns of p53-knockout P19 cells. Taken together, these results indicate that p53 is a master regulator of P19 cells responding to the ZdCyd treatment in either adherent or non-adherent growing conditions.
In conclusion, the ZdCyd treatment activates p53 of P19 cells that generates a molecular network for tumor suppression in adherent growth condition, and the suspension growth condition could rewire the ZdCyd-induced p53-regulatory network of P19 cells from suppressing to promoting tumorigenesis, suggesting that the cellular context-dependent molecular networks make the decision to be or not to be a tumor.
Discussion
In the present study, we have showed that the ZdCyd treatment activates p53 proteins of P19 cells in both adherent and non-adherent growth conditions ( Figure 2C and D) . This observation is in agreement with previous reports that wild-type p53 proteins expressed in EC cells could be activated by cancertherapeutic agents such as etoposide (Lutzker and Levine, 1996) , 5-aza-deoxycytidine (Beyrouthy et al., 2009) , retinoids, and cisplatin (Zamble et al., 1998; Curtin et al., 2001) . Our unexpected finding is that the ZdCyd-induced p53 activation promotes the tumorigenic potential of detached P19 cells, although the ZdCyd-induced p53 activation retains the tumor suppressor inhibition in attached P19 cells (Figure 1) . Furthermore, p53 knockdown by the siRNA approach results in the loss of the ZdCyd-induced tumorigenesis of detached P19 cells (Figure 6 ), supporting the observation from the p53 gain function experiment that p53 does function as oncogene in this particular condition. On the other hand, cisplatin-activated p53 did not up-regulate tumorigenesis of detached P19 cells (Figure 5) , suggesting that the synergistic effect of both the ZdCyd treatment and suspension growth condition is required for p53-induced tumorigenesis of P19 cells. In other words, the activation of p53 in detached P19 cells alone is not enough to promote tumorigenic potential.
A computational method developed in the present work (Supplementary Figure S4) reveals that this synergistic effect of both the ZdCyd treatment and suspension growth condition generates a particular p53-dominant gene-regulatory network of P19 cells that is quite different from that derived by the ZdCyd treatment and adherent growth condition ( Figure 3A) . With our newly developed NOA approach , we reveal that the p53-dominant gene-regulatory network of detached P19 cells presents the enrichment of pro-survival genes and negative regulation of cell differentiation (Supplementary Table S3 ), which should be accounted for promoting tumorigenesis of this network. On the other hand, the enrichment of positive regulation of apoptosis in the p53-dominant gene-regulatory network of attached P19 cells (Supplementary Table S3 ) is tightly associated with its property of tumor suppression.
It is well documented that p53 plays its tumor suppressor roles through triggering either apoptosis or cell-cycle arrest in a transcription-dependent and -independent manner (Vogelstein et al., 2000; Levine and Oren, 2009; Zhang et al., 2009) . However, recent reports showed that p53 may facilitate tumorigenesis by up-regulating multiple genes that counteract apoptosis and promote cell survival (reviewed in Jänicke et al., 2008 ; references herein). In their review paper, Jänicke et al. (2008) discussed a number of individual anti-apoptotic p53 targets, including TFs Slug, NF-kB, DNP73, and KLF4.
Our present work shows that the mRNA levels of two TFs Rara and Pou5f1/Oct4 are highly up-regulated and their TFAS values are significantly increased only in detached P19 cells ( Figure 2C and Supplementary Table S1 ). Importantly, based on our NOA results, we identified that these two TFs in detached P19 cells are significantly enriched in the negative regulation of cell differentiation pathways (Supplementary Table S3 ). It is known that Rara and Pou5f1 are tightly associated with tumorigenesis. A number of reports have showed that the translocation between Rara and PML genes leads to expression of the PML -Rara fusion oncoprotein that is the main cause of acute promyelocytic leukemia (Lafage-Pochitaloff et al., 1995; Le Beau et al., 2002) . Pou5f1 expression has been identified in all EC cell lines. A previous report showed that the high expression level of Pou5f1 increased the oncogenic potential of human ES cells, whereas Pou5f1 inactivation suppressed the malignant potential of the cells (Gidekel et al., 2003) . In addition, Linn et al. (2010) reported that Pou5f1 was up-regulated in drug-resistant tumor cells that presented a significant increase in tumorigenicity in vivo. Taken together, these two TFs with their targets might contribute to tumorigenesis through the p53-dominant gene-regulatory network of detached P19 cells. Since our present work shows that Rara and Pou5f1 do not directly interact with p53 in the network ( Figure 3A, right panel) , it should be worth studying how ZdCyd-activated p53 controls these TFs and then facilitates the tumorigenic potential of detached P19 cells.
Although the present study shows a special case that p53-promoted tumorigenesis of P19 cells results only from the synergistic effect of both the ZdCyd-treatment and non-adherent growing condition, this observation may provide a clue for understanding a pathological phenomenon that malignant tumor cells are resistant to anoikis. It is known that normal endothelial or epithelial cells usually trigger apoptosis after they lose adhesion from their extracellular matrix, which is called 'anoikis' (Frisch and Francis, 1994; Chiarugi and Giannoni, 2008) . On the other hand, some primary tumor cells could overcome this death-barrier when they are migrating into lymphatic and circulatory systems during metastatic process (Woods et al., 2007; Simpson et al., 2008) .
More than 100 years ago, the English surgeon Stephen Paget proposed a famous 'seed and soil' hypothesis to explain metastasis, i.e. there were extensive cross-talks between selected tumor cells (the 'seeds') and specific organ microenvironments (the 'soil'), and metastasis occurred only when the seed and soil were compatible (Fidler, 2003) . Since then, numerous studies on the molecular mechanisms of metastasis have been carried out based on this hypothesis (reviewed in Fidler, 2003 ; references herein). Our present work might deliver a new angle to study the 'seed and soil' hypothesis of metastasis. Our results suggest that a particular tissue/organ microenvironmental 'soil' can rewire the bio-molecular networks of some primary tumor cell-'seeds' to form anti-apoptotic and pro-survival molecular networks that provide the cellular molecular base to suppress anoikis.
Materials and methods
Cell culture and drug treatments P19 cells were maintained in DF12 medium (Sigma) with 10% FBS (Gibco) in 5% CO 2 incubator, and cultured in non-adherent growing condition as described previously (Xia et al., 2007) .
Plat-E cells were cultured in DMEM plus 10% FBS.
5-aza-2
′ -deoxycytidine (ZdCyd; Sigma) dissolved in dimethyl sulfoxide was added at 100 nM for 2 days (to attached cells) or 4 days (to detached cells). Cisplatin (Sigma) was added at 500 nM with medium for 12 h. Colony formation and tumor xenografts of nude mice Colony formation assays were performed as described previously (Liu et al., 2007; Xue et al., 2009) , in which cells were grown for 1 week (attached cells) or 3 weeks (detached cells) before staining. Tumorigenic potential was measured with nude mice. Briefly, athymic (nu/nu) male nude mice (5 weeks old) were maintained in the specific pathogen free condition under IBCB-approved protocol. Mice were injected subcutaneously with cells resuspended with PBS. Tumor growth was followed for 6 weeks. Tumor volumes were measured in groups, which were selected with at least two tumors in one group in order to calculate mean and SEM. Quantitative real-time PCR and western blotting Total RNAs were extracted from cells using Trizol (Invitrogen) and reverse transcribed (Takara). Primers for RT-PCR and realtime PCR are shown in Supplementary Table S5 . Real-time PCR analyses were performed using the iCycler iQ Sybr Green System (BioRad). Significance values were evaluated by Student's twotailed t-test. Protein samples were separated by SDS-PAGE and were transferred onto Immobilon-P membranes (Millipore). Proteins were detected with antibodies against p53, p21, b-actin (Santa Cruz), and p-p53 (Ser15; Cell Signaling), respectively. shRNA cloning and retrovirus production LMP-P53.1224 was used to knockdown p53 as described previously (Xue et al., 2009) . shRNAs targeting Usf1 and Pou5f1 were designed and cloned into pSIREN-RetroQ (Clontech). Oligomer for Usf1 was:
Retroviruses were produced by transfection of Plat-E cells with Lipofectamine 2000 (Invitrogen).
Pretreatment of microarray data
The Affymetrix Fluidics Station 450 was applied to measure messenger RNA expression levels of different samples. All resulting raw data were disposed with GCOS1.2. We got the scaling signals of 19295 genes in total samples. Then all data were normalized with Microarray Data Analysis Toolbox under default parameters (Knowlton et al., 2004) . Two-way ANOVA and hierarchical clustering
To choose significantly changed genes affected by related factors, we adopted two-way ANOVA, which is proved efficiently due to its low cost in computation, ability to handle the combinational effects of different factors and higher accuracy in small samples. In particular, for each gene, we considered drug (with or without), status (attached or detached), and their interaction (combinational effect) as three candidate factors to affect its expression level, and then applied two-way ANOVA to calculate P-values for which the listed candidate factors had effects on the given gene. Genes affected by at least one factor (P , 0.01) were chosen as differently expressed. We hierarchically clustered these samples with a fast optimal leaf-ordering hierarchical clustering method by specifying correlation as distance metric after standardizing data along samples (Bar-Joseph et al., 2001) .
The inference of TF activity
To infer the activity change of transcriptional factors in responding to drug in the attached and detached P19, we represent the interacting relations among cofactors, TFs, and targets with the following graphical model. P r (TFA |cofactor, TF, target) / P r (TFA|(cofactor, TF))P r (target|TFA) = P r (TFA|P 1 , · · · ,P m , TF)P r (T 1 , · · · , T n |TFA), where (TFA) represents the level of TFs activity; (cofactor, TFs) denotes levels or concentrations of proteins interacting with the TF, and the level of the TFs, i.e. P 1 ,...,P m and TFs; and (target) denotes levels or concentrations of mRNAs regulated by the TFs, i.e. T 1 , ..., T n . This formula is derived from Bayesian rule and graphical model ( Figure 2B ), which means that the perturbation of a TFA is caused by the alteration of cofactor's level, but will result in the expression change of all its targets. Note that we use the mRNA levels for cofactors and the TFs to approximate their protein levels in this work. Based on this logic, we use Boolean variable B TFA to represent whether TFA is significantly perturbed, i.e.
B TFA = (B cofactor _ B TF )^B target , where^and _ are AND and OR operations of the Boolean variables, respectively. The term B cofactor _ B TF is derived on the construction (or assumption) of TFA in Figure 2B , i.e. the perturbation of any individual component (cofactor or TF) of TFA will independently cause the change of TFA. Then, based on this Boolean formula, we evaluated the P value for each TF of P19 cells growing in attached and detached conditions, respectively, by the following formula straightforwardly derived from the above equation P TFA = max{min(P cofactor ,P TF ),P target }, where P TF represents the t-test P-value for the corresponding mRNA level of the tested TF changed by drug; P cofactor the P-value for cofactor, and P target the P-value for targets are derived from the following formulas via statistical model (x 2 assumption and random permutation), respectively:
log P(C i ),
where P(C i ) represents the P-value for the ith cofactor mRNA level changed by drug (t-test); P(T actived i ) represents the P-value for the ith activated target mRNA level changed by drug (t-test) with P(T ). These were used to judge the direction of activity change. To reduce the instability of results caused by uncompleted prior knowledge and few data points, we tried multiple parameters and different methods to obtain a distribution of the changes of TFA. To quantitatively represent the degree for which TFA had been changed, we further defined TFA score (TFAS) as -log(P TFA ).
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